NCT00004772View on ClinicalTrials.gov

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 1992

Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
DRUG

Immune globulin

All Listed Sponsors
collaborator

Ohio State University

OTHER

lead

National Center for Research Resources (NCRR)

NIH

NCT00004772 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy | Biotech Hunter | Biotech Hunter